Aurobindo Pharma Stock Forecast

Stock Price Forecast

According to 29 analysts polled by S&P Global, Aurobindo Pharma stock has a consensus rating of "Buy" and an average price target of ₹1,513. The average 1-year stock price forecast is 1.02% higher than the current stock price, while the lowest is ₹1,020 (-31.90%) and the highest is ₹1,785 (+19.17%).

Price Target: ₹1,513 (+1.02%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	₹1,020	₹1,513	₹1,550	₹1,785
Change	-31.90%	+1.02%	+3.49%	+19.17%

* Price targets were last updated on Feb 15, 2026.

Analyst Ratings

The average analyst rating for Aurobindo Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	17	15	14	15	13	13
Buy	6	6	6	6	6	6
Hold	0	0	1	1	5	5
Sell	2	2	2	2	2	2
Strong Sell	3	3	2	2	2	2
Total	28	26	25	26	28	28

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Unknown Analyst ICICI Securities No rating	ICICI Securities	Buy Maintains ₹1,425	Buy	Maintains	₹1,425	-4.86%	Feb 15, 2026
Unknown Analyst Axis Direct No rating	Axis Direct	Buy Maintains ₹1,345	Buy	Maintains	₹1,345	-10.20%	Feb 11, 2026

Financial Forecast

Revenue This Year

386.63B

from 336.53B

14.89%

from 336.53B

Revenue Next Year

425.04B

from 386.63B

9.93%

from 386.63B

EPS This Year

76.79

from 61.11

25.65%

from 61.11

EPS Next Year

88.39

from 76.79

15.11%

from 76.79

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024	Mar 31, 2025	Mar 31, 2026	Mar 31, 2027
Revenue	234.55B	248.55B	290.02B	317.24B	336.53B	386.63B
Revenue Growth	-5.33%	5.97%	16.68%	9.39%	6.08%	14.89%
Gross Profit	130.06B	132.14B	160.16B	182.40B	201.65B	231.12B
Gross Margin	55.45%	53.16%	55.22%	57.50%	59.92%	59.78%
Operating Income	33.06B	25.12B	43.92B	50.32B	50.78B	60.33B
Net Income	26.48B	19.28B	31.73B	34.86B	35.05B	45.22B
EPS	-	-	-	-	61.11	76.79
EPS Growth	-	-	-	-	2.17%	25.65%
Forward PE	12.83	12.19	17.77	15.91	18.02	19.51
Dividend / Share	9.00	3.00	4.50	-	-	5.30
Free Cash Flow	12.13B	-4.80B	-12.59B	11.52B	13.19B	22.27B
No. Analysts	-	-	-	-	-	27

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.

Revenue Forecast

Revenue	2027	2028	2029
High	408.4B
Avg	386.6B
Low	359.4B

Revenue Growth

Revenue Growth	2027	2028	2029
High	21.4%
Avg	14.9%
Low	6.8%

EPS Forecast

EPS	2027	2028	2029
High	84.70
Avg	76.79
Low	62.67

EPS Growth

EPS Growth	2027	2028	2029
High	38.6%
Avg	25.6%
Low	2.6%